AzTrials
AzTrials

Advanced Solid TumorPhase 1NCT04049903

Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors

A Phase 1 study testing MP0310 in people with Advanced Solid Tumor, run by Molecular Partners AG at 3 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the safety and tolerability of MP0310, a DARPin® therapeutic candidate for tumor targeted activation of T cells, in patients with advanced solid tumors Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumor
What is being tested?
MP0310
Could I receive a placebo?
No, everyone receives an active treatment
How many people
38 participants
Where
3 sitesFrance
Study dates
2 Sep 2019to 21 Dec 2022
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient has an advanced, histologically-proven solid tumor of one of the following types, treated with at least one line of systemic therapy, and for which approved therapies have been exhausted or for which the Investigator considers the patient ineligible or intolerant of other forms of treatment: Colorectal, Ovarian, Endometrial, Gastric, Pancreatic, Anal, Cervical, Squamous cell cancer of the head and neck, Mesothelioma, Prostate, Non-small cell lung cancer, Melanoma, Urothelial/bladder, Microsatellite instability high tumors of any type, Cutaneous squamous cell, Breast,
  • Patients have to be willing to comply with study procedures
  • ≥18 years of age
  • Mentally competent, able to understand and willing to sign the ICF
  • Eastern Cooperative Oncology Group performance status (ECOG; PS) ≤1
  • Anticipated life expectancy ≥12 weeks by Investigator judgment
Show all 24Show fewer
  • The disease is measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
  • Mandatory paired pre- and on-treatment biopsies - preferably from the same lesion - are required as follows:
  • At least 1 tumor lesion ≥10 mm amenable to percutaneous biopsy other than the target lesion used to follow response as defined by RECIST v1.1
  • For cutaneous or subcutaneous lesions, tumors should be ≥ 5mm in diameter amenable to paired biopsy by excisional or punch biopsies without unacceptable risk of a major procedural complication
  • For core needle biopsy specimens three to six 18 gauge cores should be collected. If more than 1 biopsy is planned to be taken from one lesion, the lesion should be large enough to permit successive biopsies preferably ≥1 cm apart.
  • At least 4 weeks must have elapsed from any prior major surgery. The following procedures are not considered major surgical procedure:
  • Obtaining the pre-treatment biopsy as per protocol requirements
  • Placement of a port for central venous access
  • Needle, punch or excisional biopsy of a clinically or radiographically detected lesion
  • Laboratory values at screening must be:
  • Adequate hematology: i. platelet count ≥100,000 cells/mm3 ii. absolute neutrophil count ≥1,000 cells/mm3 iii. hemoglobin ≥9 g/dL b. Serum creatinine ≤1.5 x upper limit of normal (ULN) or creatinine clearance ≥50 mL/min on the basis of CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), Cockcroft-Gault, or Modification of Diet in Renal Disease (MDRD) glomerular filtration rate estimation c. Adequate coagulation: iv. INR must be <1.5, unless on therapeutic anticoagulants v. PT and activated partial thromboplastin time (aPTT) ≤1.6 x ULN unless therapeutically warranted d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3x ULN e. Bilirubin <1.5 x ULN, except for patients with a known familial hyperbilirubinemia (such as e.g., Gilbert syndrome). For patients with documented Gilbert's syndrome (Gilbert-Meulengracht syndrome) total bilirubin <3 x ULN is acceptable) f. Potassium, calcium, and magnesium that are >0.9 of LLN and ≤1.1 of ULN. Supplementation is allowed for potassium, calcium and magnesium to reach these values
  • A woman of childbearing potential (WOCBP) should only be included after a confirmed menstrual period and a negative serum pregnancy test at Screening.
  • Where ovarian activity is being suppressed by chemotherapy, confirmation of non-pregnancy by menstrual period is not required
  • A female patient is eligible to participate if she is not pregnant, not breastfeeding (for 12 months following last dose of rituximab), and at least one of the following conditions applies:
  • Not a woman of child bearing potential (WOCBP)
  • A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of MP0310 and 12 months after the last dose of rituximab, whichever is longer.
  • Men who are not surgically sterilized (and with appropriate post vasectomy documentation of the absence of sperm in the ejaculate) and who are partners of WOCBP must be willing to use adequate contraception as detailed in Section 15.7 from the Screening visit, during the treatment period, and for at least 3 months after the last MP0310 IMP administration and refrain from donating sperm during this period.
  • Covered by healthcare insurance (if applicable, in accordance with local regulations)

Who cannot join

  • Known hypersensitivity to the following excipients that are used for formulation of MP0310:
  • L-histidine, L-histidine hydrochloride, D-mannitol and polysorbate 20
  • Patients with autoimmune diseases, except auto-immune endocrinopathies that are stable with hormone replacement therapy
  • Patients with inflammatory diseases such as arthritis, colitis, liver fibrosis, cirrhosis, interstitial fibrosis, or COPD (chronic obstructive pulmonary disease; that may have elevated tissue FAP expression) unless approved after consultation by the Medical Monitor (MM).
  • Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study for the duration of this study or the follow-up period of an interventional study
  • Patient was previously treated in this study
Show all 48Show fewer
  • Serious illness or concomitant non-oncological disease considered by the Investigator to be incompatible with participating in the protocol
  • Bisphosphonate therapy for symptomatic hypercalcemia
  • Patients on stable dose of bisphosphonate therapy or receptor activator of nuclear kappa-B ligand (RANKL)-therapy for more than 8 weeks prior to first scheduled dose of MP0310 for other reasons (e.g., bone metastasis or osteoporosis) are allowed
  • Use of an investigational agent within the past 4 weeks before first MP0310 IMP administration in this study
  • Any anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to first MP0310 IMP administration; however, the following are allowed:
  • Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists or antagonists for prostate cancer
  • Hormone-replacement therapy or oral contraceptives
  • Palliative radiotherapy for bone metastases 2 weeks prior to first MP0310 IMP administration
  • Corticosteroid use exceeding 10 mg/day prednisone or equivalent
  • Left ventricular ejection fraction of <50% on echocardiographic exam or multigated acquisition (MUGA) scan at screening
  • Any history or evidence of clinically significant cardiovascular disease defined as at least one of the following criteria:
  • Evidence of poorly controlled arterial hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)
  • Myocardial infarction or instable angina pectoris within the previous 6 months
  • Documented history of congestive heart failure of New York Heart Association >2 criteria
  • Any cardiac arrhythmia that is not well controlled
  • QT corrected (QTc) prolongation > Grade 1 (>480 ms) at screening measured on 2 separate electrocardiograms (ECGs) at least 10 minutes apart
  • Clinically significant valvular heart disease
  • Severe dyspnea, pulmonary dysfunction, or need for continuous supportive oxygen inhalation
  • Arterial thromboembolic event, stroke, or transient ischemia attack within the past 12 months
  • Patients with known central nervous system (CNS) metastasis that are either untreated or are treated but are associated with clinical symptoms (e.g., headache, convulsions). Patients with CNS metastasis that have been treated with radiotherapy and/or surgery are eligible if they are clinically without symptoms for at least 6 weeks; if under treatment with corticosteroids (not exceeding 10 mg/day prednisone or equivalent) and/or anticonvulsive agents patients must be on a stable dose for at least two weeks.
  • Any active uncontrolled bleeding, or a bleeding diathesis
  • Therapy for active infection needs to be completed at least 7 days prior to the start of therapy
  • Patients with a known positivity for human immunodeficiency virus (HIV)
  • Patients with active hepatitis B (chronic or acute; HBV) defined as having a positive hepatitis B surface antigen (HbsAg) test at screening. Patients with past or resolved HBV infection (defined as having a negative HbsAg test and a positive antibody to hepatitis B core antigen antibody test) are eligible.
  • Patients with active hepatitis C (HCV) infection defined as having a positive HCV antibody test followed by a positive HCV ribonucleic acid (RNA) test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test. Patients who are positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  • Serious or non-healing wound, skin ulcer, or non-healing bone fracture
  • Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
  • Albumin <2.8 g/dL or <28 g/L, and without albumin transfusion for ≥7 days prior to screening
  • Unwilling or unable to follow protocol requirements
  • Any live virus vaccine within 30 days prior to the start of therapy
  • Has had an allogenic tissue/solid organ transplant
  • History of another primary malignancy except for:
  • Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of investigational product and of relatively low potential risk for recurrence
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • Adequately treated carcinoma in situ without evidence of disease
  • Cancer patients with incidental histologic findings of prostate cancer that, in the opinion of the Investigator, is not deemed to require active therapy (e.g., incidental prostate cancer identified following cystoprostatectomy that is tumor/node/metastasis Stage ≤ pT2N0) may be enrolled, pending discussion and approval by the MM
  • Male or female patients of reproductive potential who are not willing to employ adequate contraception from screening to at least 3 months after the last MP0310 IMP administration
  • Any condition that, in the opinion of the Investigator, would interfere with evaluation of the MP0310 IMP or interpretation of the patient's safety or study results
  • Patient deprived of liberty by a judicial or administrative decision, patient admitted to a social institution or who is under a measure of legal protection, patient hospitalized without consent or who is in an emergency situation
  • Known hypersensitivity or allergy to murine products or any excipients of rituximab (Part C only)
  • Active, severe infections and/or severely immunocompromised state
  • Contraindication against mandatory prophylactic premedication

Trial locations and contacts

3 sites in 1 country.

France3 sites

  • Centre Léon Bérard

    Lyon, 69008

  • Institut Claudius Regaud; Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O)

    Toulouse, 31059

  • Institut Gustave Roussy

    Villejuif, 94805

Other trials in France

About this study

Official title: A First-In-Human, Single-Arm, Multi-Center, Open-Label, Repeated-Dose, Dose-Escalation Study of MP0310 in Patients With Advanced Solid Tumors

To evaluate the safety and tolerability of MP0310, a DARPin® therapeutic candidate for tumor targeted activation of T cells, in patients with advanced solid tumors

Being tested
MP0310

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MP0310Drug

    MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors

Study groups in NCT04049903
Study groupRoleWhat they receive
MP0310 Part AExperimentalEnrollment will follow a standard 3 + 3 dose escalation design. Sequential Cohorts of patients will be dosed until the MTD or unacceptable toxicity is reached. Up to 12 additional patients in total may be included at selected dose levels (up to 3).
Receives: Drug: MP0310
MP0310 Part BExperimentalweekly schedule, at least 3 and up to 24 patients evaluable for DLT assessment will be enrolled (1 to 4 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)).
Receives: Drug: MP0310
MP0310 Part CExperimentalq3w schedule implementing B-cell depletion, at least 3 and up to 12 patients evaluable for DLT assessment will be enrolled (1 to 2 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)).
Receives: Drug: MP0310

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of Adverse Events (AEs)

    According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Measured: From signing of informed consent form (ICF) until 10 weeks following the last dose or start of new anticancer therapy.

  2. Incidence of dose-limiting toxicities (DLTs)

    Dose-limiting toxicities will be reviewed as a subset of AEs that occur within the first 21 days of dosing and meet the protocol-specified criteria.

    Measured: First 21 days of dosing.

  3. Maximum tolerated dose (MTD) or a tolerated dose below MTD (if MTD is not reached)

    Based on occurrence of DLTs within a 3+3 clinical trial design

    Measured: From signing of ICF until 10 weeks following the last dose or start of new anticancer therapy.

  4. Recommended expansion dose (RED)

    Based on incidence and nature of DLTs, and incidence, nature, and severity of AEs and serious adverse events (SAEs)

    Measured: From signing of ICF until 10 weeks following the last dose or start of new anticancer therapy.

Secondary outcomes (10)

  1. Serum concentration - time profiles

    Including parameters like maximal serum concentration (Cmax), time at Cmax (Tmax), minimal serum concentration (Cmin)

    Measured: 24 months

  2. Area under the serum concentration-time curve (AUC)

    Pharmacokinetic (PK) analysis of MP0310

    Measured: 24 months

  3. Total clearance (CL)

    PK analysis of MP0310

    Measured: 24 months

  4. Volume of distribution (Vd), volume at steady state (Vss)

    PK analysis of MP0310

    Measured: 24 months

  5. Terminal elimination half-life (t1/2)

    PK analysis of MP0310

    Measured: 24 months

  6. Accumulation ratio

    PK analysis of MP0310

    Measured: 24 months

  7. Incidence of anti-drug-antibodies

    Serum concentration-time profile of anti-drug antibodies

    Measured: 24 months

  8. Objective response rate (ORR)

    The proportion of participants with confirmed complete response (CR) and partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)

    Measured: 24 months

  9. Disease control rate (DCR)

    Stable disease lasting 4 or more weeks following the initiation of MP0310

    Measured: 24 months

  10. Duration of response (DoR)

    For participants with CR or PR, DOR will be calculated as time from initial response of CR or PR to progressive disease or death.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2019
  2. Study start2 Sep 2019
  3. Primary completion27 Jun 2022
  4. Study completion21 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
38 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04049903
Sponsor's protocol ID
MP0310-CP101
Other IDs
2018-004786-13, 2018
Status last verified
Dec 2022
First submitted
5 Aug 2019
Last updated
22 Dec 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing MP0310 in people with Advanced Solid Tumor, run by Molecular Partners AG at 3 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 48 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Adverse Events (AEs) (time frame: From signing of informed consent form (ICF) until 10 weeks following the last dose or start of new anticancer therapy.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04049903.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in